Wire · opportunities
Freenome's SimpleScreen CRC gains FDA approval; $100M Abbott milestone, Medicare ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 27 July 2026 · Fusion42 review
Freenome's SimpleScreen CRC blood-based colorectal cancer screening test gained FDA approval for average-risk adults 45+, with 81.1% sensitivity for CRC and expected Medicare coverage. Abbott will exclusively commercialise the test in the US and paid a $100 million milestone, with Freenome planning to integrate it into its broader cancer screening portfolio.
This Wire brief sits within Fusion42's coverage of Diagnostics, and 4 sources have reported it between 27 Jul 2026 and 28 Jul 2026.
◆ ◆ The Wire takeaway
If you're selling into cancer screening or preventive diagnostics, a blood test just became standard of care—Medicare will pay for it, American Cancer Society will recommend it, and Abbott owns the distribution. Your customer acquisition cost and reimbursement pathway just changed.
◆ Coverage
4 sources · first reported 27 Jul 2026 · latest 28 Jul 2026
◆ Related on Wire
◆ Topics